ACVR1 and fibrodysplasia ossificans progressiva: Considering the well-characterized significance of aberrant ACVR1/ALK2 signaling in FOP pathology, several trials are in progress targeting components of this pathway; these include Activin A (NCT05394116) or the ACVR1 receptor (NCT04307953, NCT05039515, NCT05090891).